Centre Hospitalier de l’Université de Montréal-ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  3. Disability accrual in primary and secondary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717

  4. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  5. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  6. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

  2. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 1, pp. 23-30

  3. lncRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review

    International journal of oncology, Vol. 60, Núm. 5

2021

  1. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 5, pp. 755-766

  2. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  3. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score

    British Journal of Surgery, Vol. 19, Núm. 4

2020

  1. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

  2. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90

2019

  1. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, Núm. 4, pp. 458-468

2018

  1. Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 24, Núm. 12, pp. 1569-1577

2017

  1. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

    The Lancet Neurology, Vol. 16, Núm. 4, pp. 271-281

2013

  1. Breast cancer in systemic lupus erythematosus

    Oncology (Switzerland), Vol. 85, Núm. 2, pp. 117-121